SPONSOR
Sichuan Baili Pharmaceutical Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 1, Phase 3
Conditions studied: Extensive-stage Small-cell Lung CancerMultiple MyelomaHematologic MalignanciesRelapsed/Refractory Acute Myeloid Leukemia (R/R AML)Small Cell Lung CancerNon-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Extensive-stage Small-cell Lung Cancer, Multiple Myeloma, Hematologic Malignancies, Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
The trial portfolio spans Phase 2, Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sichuan Baili Pharmaceutical Co., Ltd.
How many clinical trials has Sichuan Baili Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Sichuan Baili Pharmaceutical Co., Ltd., of which 5 are actively recruiting participants. These trials cover conditions including Extensive-stage Small-cell Lung Cancer, Multiple Myeloma, Hematologic Malignancies. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sichuan Baili Pharmaceutical Co., Ltd. research focus on?
Sichuan Baili Pharmaceutical Co., Ltd. clinical trials span Extensive-stage Small-cell Lung Cancer, Multiple Myeloma, Hematologic Malignancies, Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), Small Cell Lung Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sichuan Baili Pharmaceutical Co., Ltd. clinical trial?
To participate in a Sichuan Baili Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sichuan Baili Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Sichuan Baili Pharmaceutical Co., Ltd.
NCT06437509 Phase 2
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
NCT07255898 Phase 1
Recruiting
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Multiple Myeloma
NCT05924750 Phase 1
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
NCT05924841 Phase 2
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer
NCT06838273 Phase 3
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Non-small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology